CMC & ManufacturingLast reviewed May 2026

Current Good Manufacturing Practice(cGMP)

The current quality standards FDA enforces for the manufacture, processing, packing, and holding of drug products to ensure identity, strength, quality, and purity.

Usage Examples

The PAI evaluated cGMP compliance at the commercial manufacturing facility.
cGMP batch record review identified three out-of-trend results triggering investigation.
The Warning Letter cited four categories of cGMP deficiencies across the quality system.

What is cGMP?

Current Good Manufacturing Practice (cGMP) is the FDA's codified and enforced quality baseline for pharmaceutical manufacturing. The "current" qualifier reflects that the standard evolves with manufacturing science — FDA expects manufacturers to keep pace with contemporary technology, controls, and quality management practices. The relevant regulations are 21 CFR Parts 210 (General) and 211 (Finished Pharmaceuticals) for drug products, Part 600 series for biologics, and Part 820 for medical device Quality System Regulation.

cGMP covers building and facilities, equipment, production and process controls, packaging and labeling, holding and distribution, laboratory controls, records and reports, returned and salvaged product, and personnel responsibilities. It is principle-based: regulations describe what must be done, not always how. Companies design their Quality System to meet cGMP requirements and demonstrate compliance through documented procedures, executed batch records, and QA-reviewed release decisions.

FDA inspections against cGMP are the primary enforcement mechanism. Form 483 observations document cGMP violations; Warning Letters escalate persistent or serious non-compliance. Pre-Approval Inspections (PAI) assess cGMP readiness of facilities intended for commercial manufacture before NDA or BLA approval. International harmonization (ICH Q7 for APIs, ICH Q9/Q10) aligns cGMP expectations across major jurisdictions.

Regulatory Context

This term appears most often in cmc & manufacturing workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside 21 CFR 210, 21 CFR 211, ICH Q7.

FDAICHHealth Canada

When This Matters

The PAI evaluated cGMP compliance at the commercial manufacturing facility.
cGMP batch record review identified three out-of-trend results triggering investigation.
The Warning Letter cited four categories of cGMP deficiencies across the quality system.

Common Mistakes

Failing to align CMC change narratives with current CFR/ICH expectations.
Submitting incomplete control strategy documentation.
Separating manufacturing and regulatory review cycles too late in execution.

Related Regulations

21 CFR 21021 CFR 211ICH Q7ICH Q10

Frequently Asked Questions

Both refer to the same concept — quality systems for manufacturing. "Current" explicitly emphasizes that the standard evolves: FDA expects manufacturers to adopt contemporary technology and controls, not just meet the regulation text from decades ago. Internationally, GMP and cGMP are generally used interchangeably.

Phase 1 clinical supplies have more flexible cGMP expectations (FDA 2008 guidance on Phase 1 drug products). Phase 2 and 3 clinical supplies require more rigorous cGMP, and commercial launch requires full 21 CFR 211 compliance. The exact expectations scale with clinical trial phase and risk.

Quality by Design (QbD) is a development and manufacturing philosophy that builds quality into the process; cGMP is the regulatory baseline that all manufacturing must meet. QbD-developed processes often exceed cGMP minimums by providing deep process understanding and robust control strategies, but cGMP remains the floor for every manufactured batch.